Technological Reverberations To Boost The Atrial Fibrillation Devices MarketPosted by Merin John on June 28th, 2021 Interventional electrophysiology devices have already had a significant impact on patients suffering from cardiac arrhythmias, and are being increasingly adopted as a permanent treatment option for atrial fibrillation. Procedures such as radiofrequency ablation, cryoablation, and cox-maze are well performed in today’s practice. Recent studies have found cryoablation to be more effective than medical management, and it is widely used in medical surgical practice. The overall market is primarily driven by the growing prevalence of atrial fibrillation amongst the geriatric as well as adult population, and the adoption of minimally-invasive techniques for the permanent treatment of atrial fibrillation. Moreover, the use of innovative techniques, advancements in technology, and favorable reimbursement scenario are some other factors responsible for propelling the growth of the atrial fibrillation devices market. Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31531 Companies covered in Atrial Fibrillation Devices Market Report
As such, the global atrial fibrillation devices market is estimated to be valued at US$ 3.9 Bn in 2020, with the market expected to exhibit a healthy CAGR of more than 14% during the forecast period (2020-2030). Key Takeaways from Atrial Fibrillation Devices Market Study
“New product approvals and launches of ablation catheters along with increasing demand for minimally-invasive procedures offering increased longevity and safety profiles are driving the growth of the global atrial fibrillation devices market,” says a PMR analyst. New Product Launches – Key Strategic Focus of Market Players Product approvals by the FDA for new AF devices are responsible for intense competition among market players. Numerous organizations are focusing on new product launches for electrophysiology, especially for atrial fibrillation. For instance, in August 2016, Biosense Webster, Inc., a world leader in the treatment and diagnosis of heart arrhythmias, announced the launch of THERMOCOOL SMARTTOUCH SF catheters with contact force technology and a porous tip designed to optimize the treatment of atrial fibrillation. Also, in January 2019, Abbott announced FDA approval for the TactiCath Contact Force Ablation Catheter. These winning strategies by leading players in the atrial fibrillation devices market are also being followed by regional and local players. Atrial Fibrillation Devices Market: Competition Landscape The global market is set to broaden its scope during the forecast period, stimulated by the rising prevalence of AF, worldwide. In addition, a favorable reimbursement scenario and increasing demand for minimally-invasive procedures have augmented the sales of atrial fibrillation devices. The market is dominated by 4 major manufacturers – Biosense Webster, Inc. (Johnson & Johnson), Abbott Laboratories, Medtronic Plc, and Boston Scientific Corporation, with a revenue share of over 70% in 2019. These major manufacturers are focusing on manufacturing electrophysiology devices used specifically for atrial fibrillation procedure, such as ablation devices, intracardiac echocardiography catheters, and left atrial appendage (LAA) management devices. Key market players covered by PMR include Biosense Webster, Inc. (Johnson & Johnson), Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, ArtiCure, Inc., Japan Lifeline Co., Biotronik SE & Co. KG, Biomerics, MicroPort Corporation, and CathRx, who are consolidating their position through mergers, acquisitions, and new product launches. Want more insights? PMR brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global atrial fibrillation devices market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the atrial fibrillation devices market on basis of product (diagnostics – conventional EP catheters, mapping catheters, CS catheters, and ICE catheters) and therapeutics – EP ablation, maze surgery, and LAA management devices), technology (radiofrequency, crythotherapy, ultrasound, and others), and end user (hospitals, ambulatory surgical centers, and cardiac catheterization laboratories), across seven major regions. Like it? Share it!More by this author |